An Ozempic-like medication is on track for subsidised access in Australia, with the federal government committing to list the weight-loss drug Wegovy on the Pharmaceutical Benefits Scheme (PBS) for a narrowly defined cohort: adults with an established cardiovascular disease and a body mass index (BMI) of 35 or higher. The move positions obesity treatment within the country’s core medicines program while the government weighs the fiscal impact of what Health Minister Mark Butler has called a “very big bill for taxpayers”.
Wegovy is a glucagon-like peptide-1 (GLP‑1) medication that suppresses appetite and promotes weight loss. It is already marketed internationally for chronic weight management in adults with obesity or overweight and weight‑related conditions. In Australia, the independent Pharmaceutical Benefits Advisory Committee (PBAC) recommended a tightly defined listing in late 2025. While a PBS start date has not been announced, the government has accepted PBAC’s advice in principle and is now negotiating price with manufacturer Novo Nordisk.
Once listed, the PBS would cut out‑of‑pocket costs for eligible patients from several thousand dollars a year to the standard copay levels now in effect.
“Right now, more than 400,000 Australians are paying market prices for one of the GLP-1s, and that is as much as $4,000 or $5,000 a year, which is obviously beyond the means of many Australians,” Mr Butler said on Friday.
“This is not just a health issue for us, it’s also an equity issue.”
Who would be eligible if Wegovy is listed
| Medicine | Wegovy (semaglutide), GLP‑1 receptor agonist |
| Eligibility criteria | Adults with established cardiovascular disease (e.g., prior heart attack or stroke) and BMI ≥35 |
| Purpose of listing | Chronic weight management and reduction of future cardiovascular risk in a high‑risk subgroup |
| Patient copayment (from January 1, 2026) | $25 per script (general), $7.70 per script (concession) |
| Current status | Government commitment to list, subject to price and risk‑sharing negotiations with the manufacturer; timing to be confirmed |
Scale of need and potential reach
- Severe obesity (BMI ≥35) affects an estimated 13% of Australian adults based on 2022 data, intersecting with high rates of cardiovascular disease.
- GLP‑1 medicines have been purchased out‑of‑pocket by large numbers of patients; the Health Minister cites more than 400,000 Australians facing annual costs of $4,000-$5,000.
- The proposed listing targets a smaller, highest‑risk subset to balance equity gains with budget sustainability and to avoid overwhelming the PBS with demand from lower‑risk groups.
Why prioritise patients with cardiovascular disease
- People living with severe obesity and established cardiovascular disease face substantially elevated risks of heart attack, stroke and premature mortality compared with the general population.
- GLP‑1 therapies such as semaglutide have demonstrated clinically meaningful weight loss and, in large international trials, about a 20% relative reduction in major adverse cardiovascular events for high‑risk adults with overweight or obesity and established cardiovascular disease.
- This dual benefit-weight reduction alongside cardiovascular risk lowering-aligns with focusing scarce public subsidies on the highest expected health impact and potential reductions in future hospital demand.
“To help prevent them from having another cardiovascular event or dying from cardiovascular disease,” Dr Mellor said. “It makes sense that we need to treat these people if they want that treatment.”
Budget exposure and access safeguards
- The government has signalled a “very big bill for taxpayers” if demand is not tightly managed, noting the global surge in use of GLP‑1 weight‑loss therapies.
- PBAC highlighted a significant risk of demand from people meeting only one of the thresholds (either BMI or cardiovascular disease), and flagged a risk‑sharing arrangement with the company to protect the public budget if uptake exceeds forecasts.
- Price negotiations with the manufacturer will determine final PBS costs; the government expects clearer expenditure estimates to emerge during those talks.
- Restrictive eligibility, prescriber stewardship and potential volume caps are standard tools used in PBS listings to control spending on high‑cost medicines.
- Global supply constraints for GLP‑1 products have periodically affected availability; careful rollout planning will be needed to avoid displacing treatment for other conditions, including type 2 diabetes.
Safety signals and regulatory oversight
- In early December 2025, the national medicines regulator issued an updated warning that GLP‑1 drugs could lead to potential suicidal thoughts. Ongoing pharmacovigilance, patient screening and prompt adverse‑event reporting remain essential.
- GLP‑1 therapies have known side‑effect profiles (such as gastrointestinal symptoms) and are intended for long‑term management under medical supervision rather than short‑term “quick fix” use.
- PBAC’s narrow recommendation and the prospect of a formal risk‑sharing agreement reflect a cautious approach that seeks to balance wider access with patient safety and fiscal responsibility.
Timeline at a glance
- December 2025: PBAC publishes advice recommending PBS listing for Wegovy with BMI ≥35 and established cardiovascular disease.
- Early December 2025: The World Health Organization endorses GLP‑1 medications as long‑term treatments for obesity and urges affordability and access.
- Early December 2025: Therapeutic Goods Administration updates safety warning on potential suicidal thoughts with GLP‑1 medicines.
- January 1, 2026: PBS copayments reduced to $25 per script (general) and $7.70 (concession), lowering costs across the wider medicines schedule.
- January 2026: Government indicates it will begin negotiating price with Novo Nordisk; PBS listing date for Wegovy to be confirmed once agreement is reached and supply is assured.
What this means for the health system
- Equity: Subsidy could sharply reduce out‑of‑pocket costs for a high‑risk cohort that faces substantial disease burden and financial barriers, narrowing the gap between those who can self‑fund GLP‑1 drugs and those who cannot.
- Population health: Targeted access may prevent recurrent cardiovascular events and reduce downstream hospitalisations over time, with benefits concentrated among those at greatest risk.
- System capacity: Rollout will require planning across primary care and specialist clinics to manage demand, monitor outcomes and coordinate supply, including clear guidance to prescribers on PBS criteria.
- Governance: A risk‑sharing framework, clear eligibility rules and active safety monitoring will be pivotal to sustainable implementation, testing how the PBS responds to a new class of long‑term, lifestyle‑adjacent therapies.
Where Ozempic fits now
- Ozempic remains PBS‑listed only for type 2 diabetes, reflecting the original indication for GLP‑1 medicines.
- The proposed Wegovy listing would create a separate PBS pathway limited to severe obesity with established cardiovascular disease, distinct from diabetes indications and with its own prescriber and monitoring requirements.
- Both products contain semaglutide but are approved and dosed for different clinical uses, underscoring the need for precise eligibility, patient counselling and monitoring under the PBS.
The policy choice now before government is not whether obesity should be treated, but how to steward a high‑impact therapy within a universal medicines program-maximising health gains for those at greatest risk while managing costs, supply and safety with care.
Worth a look
